### **Edelweiss Professional Investor Research**

PROFESSIONAL INVESTOR
RESEARCH

PMS • AIF • Prop Funds • Family offices



PMS • AIF • Prop Funds • Family offices

### Diwali Picks 2016-17

### 1 Year Price **Returns Diwali Picks** Entry Bajaj Finance 1115 1727 55% Kotak Mahindra Bank 780 987 26% Motherson Sumi 218 324 50% PC Jewellers 252.5 356 41% Portfolio Returns 43% Nifty Index 14% Alpha 29%

### Diwali Picks 2017-18

| Diwali Picks       | Entry | 1 Year Price | Returns |
|--------------------|-------|--------------|---------|
| National Aluminium | 82    | 70           | -15%    |
| NIIT Technologies  | 595   | 1164         | 96%     |
| Bharat Forge       | 640   | 585          | -9%     |
| Radico Khaitan     | 172   | 404          | 135%    |
| MCX                | 1103  | 700          | -37%    |
| Average            |       |              | 34%     |
| Mid Cap            |       |              | -7%     |
| Alpha              |       |              | 41%     |

| Stocks To Buy              | Entry | Potential Target |
|----------------------------|-------|------------------|
| Axis Bank Ltd              | 603   | 900              |
| Aurobindo Pharma Ltd       | 790   | 1200             |
| PVR Ltd                    | 1423  | 1850             |
| Muthoot Finance Ltd        | 445   | 700              |
| Firstsource Solutions Ltd  | 57    | 100              |
| Potential Portfolio Return |       | 53%              |

<sup>\*</sup> Assuming equal investment in each stock

# Sector Developments

PMS • AIF • Prop Funds • Family offices

**Banking**: Axis Bank Ltd surprised investors by reporting a cracker of a performance for the second quarter. The private sector lender's net profit jumped a stupendous 83% because of lower provisioning. Axis Bank's slippages fell to ₹2,777 crore, the lowest in six quarters. The in the leadership position could be an added catalyst.



**Pharma:** The sector outlook has remained gloomy and in a consolidation for the last 3-4 years. However in mid 2018 we seen the equal weighted chart of the pharma index break out of its consolidation. Along side large cap pharma stocks beating street expectation in the previous quarter results.



**Media:** With rising geographical presence and ability to raise ticket prices across properties, PVR is expected to generate 18-25 per cent revenues growth for the remaining part of the present fiscal year. During the quarter under review, the company's revenues growth of 28 per cent to Rs 714 crore beat Street estimates of 21 per cent growth.



PROFESSIONAL INVESTOR
RESEARCH

PMS • AIF • Prop Funds • Family offices

**NBFC:** The NBFC sector has been the outperformer in this bull rally, however post the sept-oct NBFC crash most of the NBFCs are down 20-25%. The sector exposure of those NBFCs were in the real estate and housing market, but majorly all NBFC,s witnessed a correction. Post the correction, Muthoot finance has started to outperform other NBFCs, while housing finance companies still face downward pressure.



IT: Mid cap IT stocks seen a huge run up in the previous year, FSL was one of the outperformers as the stock gave a return of 145% in in less than a year. It was also one of the first stocks to correct, almost correcting 35% from its recent June highs. The current trend in the Midcap IT stocks have almost reached the end of the corrective phase.



# Buy Axis Bank CMP 603, MCAP INR 1,55,074 Cr.

2007

2008

AXSB IS Equity (Axis Bank Ltd) Special Chart Weekly 06NOV2016-06NOV2018

2009

2010

2011

2006



AXSB IS Equity - Last Price 206.33 . ☐ Span **-**1000 . Span 72.36 ι ⊓ Trend **►**800 ι ⊓ Horizontal n.a. **≻**700 603.45 **-**500 **-**200 **►**100

\* Stock has completed a 180 week correction/consolidation phase as highlighted in the chart. Post the previous breakout in 2014 we seen the stock give a substantial return. Currently the stock has bounced from its long term trendline and is trading near to its all time high levels. We expect the stock to touch 900 in the next 12-15 months.

2013

2014

Copyright@ 2018 Bloomberg Finance L.P.

2015

2016

2017


2018

06-Nov-2018 11:42:31


2012

### Buy Auro Pharma CMP 790, MCAP INR 45,885 Cr.






\* AuroPharma is has broken out of its channel pattern /consolidation phase, the stock has also retested its channel breakout levels and bounced to its 52 week highs. Currently on the smaller timeframe stock has broken out of its flag pattern. We can expect a target of 1200 in the next 12-15 months.



\* PVR is in an uptrend since 2012, the stock has been consolidating in the last eight months. The stock is near its channel breakout. On the shorter timeframe stock has broken out of its inverse H&S pattern indicating the momentum could bring in a larger breakout of the consolidating channel. We could see the stock touch 1850 in the next 12-15 months.

# Buy Muthoot Finance CMP 445, MCAP INR 17,883 Cr.






\* Since the uptrend starting in 2013 stock has moved in an upward sloping channel keeping a drawdown of 30% approx, currently the stock has completed a similar drawdown and reversed. Trading near a breakout, we expect the stock to pick momentum and achieve a target of 700 according to the upward sloping channel.


# Buy Firstsource Solutions Ltd. CMP 57, MCAP INR 4000 Cr.





\* First Source Itd has retested its previous break out level after hitting a 10 year high. The stock is expected to bounce from this demand area to resume its uptrend and could achieve a target of 100 in the next 12-15 months





### Disclaimer

PROFESSIONAL INVESTOR
RESEARCH

PMS • AIF • Prop Funds • Family offices

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its Associates (list available on www.edelweissfin.com) are organized around five broad business groups — Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

Broking services offered by Edelweiss Broking Limited under SEBI Registration No.: INZ000005231; Name of the Compliance Officer: Mr. Brijmohan Bohra, Email ID: complianceofficer.ebl@edelweissfin.com Corporate Office: Edelweiss House, Off CST Road, Kalina, Mumbai - 400098; Tel. 18001023335/022-42722200/022-40094279

#### Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations)

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups — Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited ("Edelweiss") in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No.INH000000172

This Report has been prepared by Edelweiss Broking Limited in the capacity of a Research Analyst having SEBI Registration No.INH000000172 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This information is not increasing in any locality, state, country or other jurisdiction, where such distribution or which would be contrary to law, regulation or which would subject EBL and associates / group companies to any registration in the certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events with the understanding the proposed of the propose of the

EBL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the EBL to present the data. In no event shall EBL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the EBL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

EBL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. EBL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with EBL.

EBL or its associates may have received compensation from the subject company in the past 12 months. EBL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or EBL's associates may have financial interest in the subject company. EBL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

#### EBL has financial interest in the subject companies: No

EBL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

EBL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

#### Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

#### Additional Disclaimer for U.S. Persons

Edelweiss is not a registered broker – dealer under the U.S. Securities Exchange Act of 1934, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. In addition Edelweiss is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Edelweiss, including the products and services described herein are not available to or intended for U.S. persons.

This report does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.

Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

#### Additional Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant person who is not a relevant person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

#### Additional Disclaimer for Canadian Persons

Edelweiss is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Edelweiss, including the products and services described herein, are not available to or intended for Canadian persons.

This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.